Toshio Hasegawa1, Tomoyuki Matsukura, Shigaku Ikeda. 1. Department of Dermatology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan. t-hase@med.juntendo.ac.jp
Abstract
BACKGROUND: Benign symmetric lipomatosis, also known as Madelung disease, is a rare disorder characterized by fat distribution around the shoulders, arms, and neck in the context of chronic alcoholism. Complete excision of nonencapsulated lipomas is difficult. However, reports describing conservative therapeutic measures for lipomatosis are rare. METHODS: The authors present the case of a 42-year-old man with a diagnosis of benign symmetric lipomatosis who had multiple, large, symmetrical masses in his neck. Multiple phosphatidylcholine injections in the neck were administered 4 weeks apart, a total of seven times to achieve lipolysis. RESULTS: The patient's lipomatosis improved in response to the injections, and he achieved good cosmetic results. CONCLUSIONS: Intralesional injection, termed mesotherapy, using phosphatidylcholine is a potentially effective therapy for benign symmetric lipomatosis that should be reconsidered as a therapeutic option for this disease.
BACKGROUND: Benign symmetric lipomatosis, also known as Madelung disease, is a rare disorder characterized by fat distribution around the shoulders, arms, and neck in the context of chronic alcoholism. Complete excision of nonencapsulated lipomas is difficult. However, reports describing conservative therapeutic measures for lipomatosis are rare. METHODS: The authors present the case of a 42-year-old man with a diagnosis of benign symmetric lipomatosis who had multiple, large, symmetrical masses in his neck. Multiple phosphatidylcholine injections in the neck were administered 4 weeks apart, a total of seven times to achieve lipolysis. RESULTS: The patient's lipomatosis improved in response to the injections, and he achieved good cosmetic results. CONCLUSIONS: Intralesional injection, termed mesotherapy, using phosphatidylcholine is a potentially effective therapy for benign symmetric lipomatosis that should be reconsidered as a therapeutic option for this disease.
Authors: Henryk Witmanowski; Łukasz Banasiak; Grzegorz Kierzynka; Jarosław Markowicz; Jerzy Kolasiński; Katarzyna Błochowiak; Paweł Szychta Journal: Postepy Dermatol Alergol Date: 2017-08-02 Impact factor: 1.837